FREEMAN KEVIN D

SEC Form 4 insider trading activity

FREEMAN KEVIN D has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Dec 23, 2025.

On the most recent filing, FREEMAN KEVIN D is listed as Director at GALECTIN THERAPEUTICS INC. Inside the rolling window, FREEMAN KEVIN D reported 1 open-market purchase totaling $20K in GALT and no open-market sales.

Companies traded

Other insiders at GALT

Insider Buying

$20K

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Companies

1

in the rolling window

Source
GALT
FREEMAN KEVIN D
Purchase$20KDec 23SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has FREEMAN KEVIN D made?

FREEMAN KEVIN D has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company since 2025.

Which companies does FREEMAN KEVIN D trade?

FREEMAN KEVIN D has filed SEC Form 4 disclosures for 1 company, including GALT.

When was FREEMAN KEVIN D's most recent SEC Form 4 filing?

FREEMAN KEVIN D's most recent SEC Form 4 filing on Tracefour is dated Dec 23, 2025.

What is FREEMAN KEVIN D's total buy and sell value in the current window?

Inside the rolling retention window, FREEMAN KEVIN D bought $20K and sold $0 based on SEC Form 4 filings.

What was FREEMAN KEVIN D's largest disclosed transaction?

The largest disclosed transaction in the current window is a purchase of 5,500 GALT shares on 2025-12-23, worth $20K, per SEC Form 4 filings.